KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Deffered Revenue: 2020-2025

Historic Non-Current Deffered Revenue for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $111.2 million.

  • Recursion Pharmaceuticals' Non-Current Deffered Revenue rose 607.76% to $111.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.2 million, marking a year-over-year increase of 607.76%. This contributed to the annual value of $118.8 million for FY2024, which is 131.79% up from last year.
  • Recursion Pharmaceuticals' Non-Current Deffered Revenue amounted to $111.2 million in Q3 2025, which was down 11.91% from $126.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $129.6 million in Q1 2025 and a low of $6.7 million during Q4 2021.
  • Over the past 3 years, Recursion Pharmaceuticals' median Non-Current Deffered Revenue value was $51.4 million (recorded in 2023), while the average stood at $69.1 million.
  • In the last 5 years, Recursion Pharmaceuticals' Non-Current Deffered Revenue spiked by 953.86% in 2022 and then crashed by 69.42% in 2024.
  • Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Non-Current Deffered Revenue stood at $6.7 million in 2021, then soared by 953.86% to $70.3 million in 2022, then declined by 27.07% to $51.2 million in 2023, then skyrocketed by 131.79% to $118.8 million in 2024, then skyrocketed by 607.76% to $111.2 million in 2025.
  • Its Non-Current Deffered Revenue was $111.2 million in Q3 2025, compared to $126.2 million in Q2 2025 and $129.6 million in Q1 2025.